Pharmaceuticals

Zhongheng Group

Zhongheng Group released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 355.19 M, actual EPS CNY -0.0105

Zhongheng Group FY2026 Q1 Earning Release on April 30, 2026 After-Market (BJT)

Zhongheng Group released FY2025 earnings on March 30 After-Market (BJT), actual revenue CNY 1.749 B, actual EPS CNY -0.1144

Zhongheng Group released FY2025 Q4 earnings on March 30 After-Market BJT, actual revenue CNY -199.54 M, actual EPS CNY -0.1268

Zhongheng Group FY2025 Earnings Release Scheduled for March 31, 2026 After-Market BJT

Zhongheng Group released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 497.08 M, actual EPS CNY -0.0008

Zhongheng Group released FY2025 9 Months Earnings on October 30 During-Market (BJT), actual revenue CNY 1.948 B, actual EPS CNY 0.0073

Zhongheng Group FY2025 Q3 Earnings Release on October 31 During-Market BJT

Zhongheng Group released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue CNY 709.02 M, actual EPS CNY 0.0026

Zhongheng Group released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), Actual Revenue CNY 1.451 B, Actual EPS CNY 0.0082

Zhongheng Group to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Zhongheng Group Successfully Acquired Chronic Heart Failure Drug Project

Guangtou Group Plans to Increase Guangtou Financial Holding with Shares of Zhongheng Group

Zhongheng Group Repurchased 42.147 Million Shares

Zhongheng Group released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 742.03 M, actual EPS CNY 0.0055

Zhongheng Group to Release FY2025 Q1 Earnings on April 30 After-Market BJT

Zhongheng Group Plans to Buy Back Shares of No Less Than 300 Million Yuan, Expected Buyback Quantity of 78.9474 Million to 132 Million Shares

Zhongheng Group released FY2024 Q4 earnings on March 28 After-Market (BJT), actual revenue CNY 177.9 M, actual EPS CNY -0.1185

Zhongheng Group released FY2024 Annual Earnings on March 28 After-Market (BJT), actual revenue CNY 2.105 B, actual EPS CNY -0.1119

Zhongheng Group FY2024 Annual Earnings Release on March 29, After-Market BJT

000750

600252

Sealand Securities announced that its actual controller, Guangxi Investment Group, has completed a shareholding structure adjustment with its holding subsidiary, Guangtou Jinkong. Guangtou Jinkong obtained 859 million shares of Zhongheng Group through capital increase, becoming the controlling shareholder of Zhongheng Group and holding 10.60% of Sealand Securities. This adjustment does not affect the company's control rights, and part of the shares will be locked until November 17, 2028

Zhitong

Sealand Securities

Sealand Securities: The concerted actors of the actual controller have completed the internal equity structure adjustment and share transfer

Zhongheng Group announced that its revenue for the third quarter was 497 million yuan, a year-on-year decrease of 3.65%; the net profit loss was 2.4372 million yuan. The revenue for the first three quarters was 1.948 billion yuan, a year-on-year increase of 1.10%; the net profit was 24.6404 million yuan, a year-on-year increase of 119.61%

Zhongheng Group: Net profit loss of 2.4372 million yuan in the third quarter

Zhongheng Group announced that in the first half of 2025, operating revenue was 1.451 billion yuan, a year-on-year increase of 2.84%. Net profit was 27.0776 million yuan, a year-on-year increase of 23.59%

Zhongheng Group: Net profit of 27.0776 million yuan in the first half of 2025, a year-on-year increase of 23.59%

Zhongheng Group announced that its wholly-owned subsidiary Zhongheng Innovation has acquired a technology for treating chronic heart failure from China Rongtong Scientific Research Institute Group Co., Ltd. through a transfer method, with a transaction price of RMB 55 million. This transaction does not constitute a related party transaction and does not constitute a major asset reorganization. This transaction has been approved by the 29th meeting of the 10th Board of Directors of the company and does not require submission to the shareholders' meeting for approval

Zhongheng Group: Wholly-owned subsidiary Zhongheng Innovation acquires a drug technology for treating chronic heart failure for 55 million yuan

Zhongheng Group: Has repurchased 99.5909 million shares, with a total amount of funds used of 249 million yuan

Zhongheng Group: Has repurchased 99.5909 million shares, with a total amount of funds used of 249 million yuan

LaiMei Pharmaceutical announced that its indirect controlling shareholder GuangTou Group plans to increase the capital of its subsidiary GuangTou JinKong by using the 859 million shares of Zhongheng Group it holds. This transaction falls under the category of state-owned equity changes under the same control. After the transaction is completed, GuangTou JinKong will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will still be the actual controller of the company. The aforementioned equity change is still in the planning stage and needs to go through state-owned asset approval procedures and related legal procedures

Lummy

LaiMei Pharmaceutical: Guangtou Group plans to increase capital and expand shares in Guangtou JinKong with 25.94% of Zhongheng Group shares

Zhongheng Group repurchased shares for the first time on April 10, 2025, and as of April 30, a total of 42.147 million shares have been repurchased, accounting for 1.2720% of the total share capital. The repurchase price ranged from 2.30 yuan to 2.44 yuan, with a total expenditure of 101 million yuan (excluding transaction fees)

Zhongheng Group has repurchased a total of 42.147 million shares, costing 101 million yuan

Zhongheng Group's wholly-owned subsidiary, Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd., has received the clinical trial notification for Sanqi Granules approved by the National Medical Products Administration. This drug will be used for Phase II and III clinical trials for chronic glomerulonephritis, meeting the drug registration requirements

Zhongheng Group's wholly-owned subsidiary has received the approval notice for drug clinical trials

Zhongheng Group plans to repurchase shares for between 300 million and 500 million yuan, with a repurchase price not exceeding 3.8 yuan per share. This repurchase will be used for cancellation and reduction of registered capital, with an expected number of repurchased shares ranging from 78.9474 million to 132 million shares, accounting for 2.35%-3.92% of the total share capital. The repurchase period will not exceed 6 months from the date of approval by the shareholders' meeting, with funding sourced from self-owned funds or self-raised funds, aimed at enhancing investor confidence and promoting a reasonable return of stock value

Zhongheng Group: Plans to repurchase shares for 300 million to 500 million yuan

Zhongheng Group(600252.SH)

Sealand Securities: The concerted actors of the actual controller have completed the internal equity structure adjustment and share transfer

Zhongheng Group: Net profit loss of 2.4372 million yuan in the third quarter

Zhongheng Group: Net profit of 27.0776 million yuan in the first half of 2025, a year-on-year increase of 23.59%

Zhongheng Group: Wholly-owned subsidiary Zhongheng Innovation acquires a drug technology for treating chronic heart failure for 55 million yuan

Zhongheng Group: Has repurchased 99.5909 million shares, with a total amount of funds used of 249 million yuan

LaiMei Pharmaceutical: Guangtou Group plans to increase capital and expand shares in Guangtou JinKong with 25.94% of Zhongheng Group shares

Zhongheng Group has repurchased a total of 42.147 million shares, costing 101 million yuan

Zhongheng Group's wholly-owned subsidiary has received the approval notice for drug clinical trials

Zhongheng Group: Plans to repurchase shares for 300 million to 500 million yuan